These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 5918438)

  • 1. [Latent redox potential of blood. With special reference to its behavior in multiple sclerosis].
    Holm V
    Ugeskr Laeger; 1966 Sep; 128(39):1158-62. PubMed ID: 5918438
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetic studies on changes in the redox state of in vitro incubation of peripheral blood from multiple sclerosis patients under partial anaerobic conditions.
    Holm V
    Dan Med Bull; 1981 Apr; 28(2):78-82. PubMed ID: 7249692
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the degradation of cephalin by serum enzymes of normal and diseased persons with special reference to multiple sclerosis].
    SCHMALE H
    Confin Neurol; 1960; 20():424-51. PubMed ID: 13747868
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum aldolase activity with special reference to multiple sclerosis, schizophrenia & alcoholism].
    JUVETH L
    Z Klin Med; 1957; 154(6):569-79. PubMed ID: 13558346
    [No Abstract]   [Full Text] [Related]  

  • 5. [The behavior of blood protein fractions in multiple sclerosis].
    DANIELCZYK W; KRIVANEC E
    Wien Klin Wochenschr; 1954 Jul; 66(29):512-6. PubMed ID: 13205961
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients.
    Grieb P; Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):323-7. PubMed ID: 8744654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J; Gibbs E
    Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunosuppressive therapy and humoral immunity in multiple sclerosis].
    Mavra M
    Srp Arh Celok Lek; 1980 Nov; 108(11):1139-48. PubMed ID: 7313825
    [No Abstract]   [Full Text] [Related]  

  • 9. [Haematological changes following long-term treatment of multiple sclerosis and myasthenia with azathioprin (author's transl)].
    Haas J; Patzold U
    Nervenarzt; 1982 Feb; 53(2):105-9. PubMed ID: 6801533
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum demyelinating factors in multiple sclerosis.
    Seil FJ; Westall FC; Romine JS; Salk J
    Ann Neurol; 1983 Jun; 13(6):664-7. PubMed ID: 6192755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients.
    Zamani A; Rezaei A; Khaeir F; Hooper DC
    Clin Neurol Neurosurg; 2008 Jun; 110(6):642-3. PubMed ID: 18471958
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone.
    Kopff M; Zakrzewska I; Klem J; Puczkowski S; Strzelczyk M; Czernicki J; Chmielewski H
    Pol J Pharmacol; 1995; 47(6):525-30. PubMed ID: 8868375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cortisol suppression in corticoid therapy. Comments on the contribution by R. Voltz and R. Hohlfeld. Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids].
    Haupts M; Schlüter T; Gehlen W
    Nervenarzt; 1993 Jun; 64(6):413. PubMed ID: 8332236
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
    Hoffmann LA; Krumbholz M; Faber H; Kuempfel T; Starck M; Pöllmann W; Meinl E; Hohlfeld R
    Neurology; 2007 Mar; 68(12):958-9. PubMed ID: 17372138
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical impressions on the treatment of multiple sclerosis with thymus factor.
    Cendrowski W
    Schweiz Arch Neurol Neurochir Psychiatr; 1980; 127(2):199-203. PubMed ID: 6169140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein and lipide studies in multiple sclerosis.
    ROBOZ E; HESS WC; TEMPLE DM; FORSTER FM
    Trans Am Neurol Assoc; 1954; 13(79th Meeting):211-4. PubMed ID: 13238366
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood groups in multiple sclerosis].
    Wender M; Przybylski Z; Stawarz M; Chmielewska U
    Pol Tyg Lek; 1980 Oct; 35(43):1637-9. PubMed ID: 7255249
    [No Abstract]   [Full Text] [Related]  

  • 19. Zinc in multiple sclerosis.
    Dore-Duffy P; Catalanotto F; Donaldson JO; Ostrom KM; Testa MA
    Ann Neurol; 1983 Oct; 14(4):450-4. PubMed ID: 6195958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination.
    Antony JM; van Marle G; Opii W; Butterfield DA; Mallet F; Yong VW; Wallace JL; Deacon RM; Warren K; Power C
    Nat Neurosci; 2004 Oct; 7(10):1088-95. PubMed ID: 15452578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.